The cathepsin-S/protease-activated receptor-(PAR)-2 axis drives chronic allograft vasculopathy and is a molecular target for therapeutic intervention.

Martin RyllYutian LeiMichael N ThomasMingming LiBernhard RenzUlrich WirthFlorian KühnAlexandr BazhinJens WernerHans-Joachim AndersJoachim Andrassy

Published in: Transplant immunology (2023)

In conclusion, our data indicate that inhibiting CatS and PAR-2 deficiency led to a marked reduction of neointima formation and associated inflammation in a murine heterotopic model for allograft vasculopathy.

Keyphrases

kidney transplantation
randomized controlled trial
oxidative stress
electronic health record
signaling pathway
replacement therapy
single molecule